Avon Products Inc. (NYSE: AVP) extended its gains in late trading Tuesday, changing hands at $9.18, up nearly 6 percent. The multi-level marketer is considering strategic alternatives including the sale of its North American business, according to a report in The Wall Street Journal.
RadiSys Corporation (NASDAQ: RSYS) jumped more than 10 percent in the after-hours session, changing hands at $2.19. The wireless infrastructure company said it expects to post first-quarter earnings of $0.03 a share, above its previous midpoint guidance of $0.01 a share.
Media General Inc (NYSE: MEG) rose more than 3 percent to $16.70. The company said earlier this month that Standard General Communications LLC will sell 6.8 million Media General shares at $16 a piece in an offering expected to close April 17.
CSX Corporation (NYSE: CSX) rose 3 percent to $34.20 after the bell when the railroad company posted quarterly earnings.
Biogen Inc (NASDAQ: BIIB) gained nearly 3 percent to $433 after the company issued results of a Phase II study of its optic neuritis treatment that showed statistically significant improvement for patients.
Intel Corporation (NASDAQ: INTC) rose more than 3 percent to $32.50 after the bell on news that its first-quarter results were in line with expectations. The company's outlook was mixed.
GoPro Inc (NASDAQ: GPRO) gained nearly 2 percent to $45.25 amid a Piper Jaffray upgrade.
Sanmina Corp (NASDAQ: SANM) recouped its earlier losses in the extended session Tuesday. The electronics manufacturing services provider didn't issue any news.
RadNet Inc. (NASDAQ: RDNT) bounced up 4 percent to $9.07 following Tuesday's closing bell. The outpatient diagnostic imaging services company acquired New York Radiology Partners of Manhattan for $34 million.
GrafTech International Ltd (NYSE: GTI) dipped 5 percent to $4.03 during late trading after gaining 5 percent in the regular session. The maker of graphite products didn't issue any news.
See more from Benzinga
-
Analyst Sees Buying Binge For Brookfield Infrastructure Partners
-
Analyst Wants Proof On Arrowhead Research's Hepatitis B Drug
-
Analyst Sees Steel-Dumping Case On Horizon, Launches Sector Coverage
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.